← Back to work
Works cited by this work
69 works
Work: The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor efficacy of radiotherapy
Immunogenic cell death and DAMPs in cancer therapy
Dmitri V. Krysko, Abhishek D. Garg, Agnieszka Kaczmarek +3
Review article20124 citationsABIDetection of immunogenic cell death and its relevance for cancer therapy
Jitka Fučíková, Oliver Kepp, Lenka Kašíková +7
Review article20203 citationsABISafety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer +27
Article20123 citationsABIPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener +4
Review article20163 citationsABIUsing immunotherapy to boost the abscopal effect
Wilfred Ngwa, Omoruyi Credit Irabor, Jonathan D. Schoenfeld +3
Review article20183 citationsABIL-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors
Kwangsoo Kim, Jae‐Ho Jeong, Daejin Lim +9
Article20152 citationsABIMitochondrial dysfunction and oxidative stress in heart disease
Jessica N. Peoples, Anita Saraf, Nasab Ghazal +2
Review article20192 citationsABIReactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion
Andromachi Kotsafti, Marco Scarpa, Ignazio Castagliuolo +1
Review article20202 citationsABIAnti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
Jihane Boustani, Benoît Lecoester, Jérémy Baude +4
Review article20212 citationsABI